# Kronox Lab Sciences share price today (Kronox Lab Sciences Ltd, NSE: KRONOX)

> Kronox Lab Sciences share price today: ₹197.70 at the NSE close on 3 November 2026. Kronox Lab Sciences (NSE: KRONOX) is worth ₹734 crore and trades at a P/E of 25.7. > Kronox Lab Sciences Ltd is reporting record margins. KRONOX · Speciality Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹197.70
- P/E: 25.7× (higher than 65% of the last 2.4 years)
- Revenue (Jun 2026): ₹28.4 Cr (+16.9% on a year ago)
- Profit (Jun 2026): ₹7.3 Cr (+16.2% on a year ago)
- Operating margin: 31.7% (−1.1 points on a year ago)
- ROCE: 36%, FY26
- ROIC: 35.7%, against a 12.0% cost of capital: +23.7 points

The main question: promoters moved −9.9 percentage points over 8 quarters while the business went the other way. ## What is the Kronox Lab Sciences share price today? Kronox Lab Sciences Ltd's share price was ₹197.70 at the close on 3 November 2026. It has been rising for 18 weeks. That is 21.0% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 15 weeks in a row. Since its first close in our records, on 15 May 2026, it has traded between ₹132 and ₹217, and at that close it sat 78% of the way up from that low. Over the last 6 months the share price moved +50% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Kronox Lab Sciences this quarter? 9 points in one quarter, profit up on a year earlier for 8 quarters in a row and indian funds and insurers (DIIs) raised their stake for 5 quarters in a row. 1. Promoters cut their stake by 9.9 points in one quarter From 74.2% to 64.3% in the September 2026 quarter. 2. Profit up on a year earlier for 8 quarters in a row In the June 2026 quarter profit was ₹7 crore, +16.2% on a year earlier. 3. Indian funds and insurers (DIIs) raised their stake for 5 quarters in a row From 1.7% to 2.5% of the company by the September 2026 quarter. ## What are Kronox Lab Sciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Kronox Lab Sciences reported revenue of ₹28.4 crore, up 16.9% from ₹24.3 crore a year earlier, and a profit of ₹7.30 crore, up 16.2% from ₹6.28 crore. ### Kronox Lab Sciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹28.4 crore | ₹24.3 crore | +16.9% |
| Profit | ₹7.30 crore | ₹6.28 crore | +16.2% |
| Earnings per share | ₹1.97 | ₹1.69 | +16.6% |
| Operating margin | 31.7% | 32.8% | −1.1 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Kronox Lab Sciences share price history? Kronox Lab Sciences closed at ₹197.70 on 3 November 2026. Its highest weekly close since May 2026 was ₹216.90 on 28 September 2026. ### Kronox Lab Sciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹189.26 | +4.5% |
| 1 month ago · 1 Oct 2026 | ₹205.77 | −3.9% |
| 6 months ago · 15 May 2026 | ₹131.55 | +50.3% |
| Earliest and lowest weekly close in our records · 15 May 2026 | ₹131.55 | +50.3% |
| Highest weekly close since May 2026 · 28 Sep 2026 | ₹216.90 | −8.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (28 weekly closes from 15 May 2026 to 3 November 2026.)

## What is the latest news on Kronox Lab Sciences? 3 Nov 2026: Kronox Lab Sciences closed at ₹197.70, up 4.5% on the week and down 3.9% on the month. Our read, 10 Oct 2026: Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration. ### Earlier

- 9 Sep 2026: ex-date for a dividend of ₹0.50 a share. - Results for April to June 2026: Revenue up 16.9% and profit up 16.2% on a year earlier. ### Our read of the business

Bronze evidence depth supports a cautious forward view. April to June 2026: Sales growth improved, but operating margin diluted. (Our read after the April to June 2026 results, written 10 October 2026.)

## What dividend does Kronox Lab Sciences pay? Kronox Lab Sciences paid ₹0.50 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.25% at the ₹197.70 close on 3 November 2026. The last was a dividend of ₹0.50 a share, ex-date 9 September 2026. ### Kronox Lab Sciences dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 9 Sep 2026 | ₹0.50 | Dividend |
| 8 Aug 2025 | ₹0.50 | Dividend |
| 23 Aug 2024 | ₹0.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Kronox Lab Sciences Ltd paid out 7% of its profit as dividends in FY26, and it paid a dividend in 3 of its last 7 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Kronox Lab Sciences management say on the latest results call? Kronox Lab Sciences' management made 0 promises we could check against what it later reported. (Our read after the April to June 2026 results, written 10 October 2026.)

## What is the future of Kronox Lab Sciences? What is changing in the business? What is changing at Kronox Lab Sciences, from the latest results and calls: sales recovery, cash-funded operating base and qualified product offering. - Sales recovery. Latest sales growth offers a demand signal, but margin dilution limits the profit benefit. ✓ fact
- Cash-funded operating base. Aggregate cash conversion gives the business room to finance growth internally. ⚠ estimate
- Qualified product offering. The company manufactures high-purity chemicals to specified industry standards. ✓ fact
- Conditional Dahej expansion. Dahej can add a growth route once construction and customer demand are demonstrated. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the April to June 2026 results, written 10 October 2026.)

## What could change the Kronox Lab Sciences story? What are the risks? A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. ### Each change stops working if

- Sales recovery: Sales growth reverses and operating profit falls in the next reported quarter. - Cash-funded operating base: Operating cash conversion deteriorates while expansion expenditure increases. - Qualified product offering: Product compliance failures interrupt sales or customers require price concessions that reduce operating profit. ### The main risks

- : Interest income makes reported profit growth look faster than operating growth. ⚠ estimate
- : Delayed Dahej construction pushes out the expansion contribution. ✓ fact
- : Latest margin dilution weakens the operating-leverage interpretation. ⚠ estimate
- : Inventory and receivables absorbed more cash in the latest year. ⚠ estimate

(Our read after the April to June 2026 results, written 10 October 2026.)

## What to watch in Kronox Lab Sciences' next results? When Kronox Lab Sciences reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: Reported profit increases while operating profit stagnates or declines. - What to check ()
- Reported profit increases while operating profit stagnates or declines. - The next project update still reports no construction commencement. - Operating margin falls below the latest reported level while revenue fails to grow. - Inventory days rise again and operating cash conversion declines. - A proposed earnings acceleration depends on unreconciled historical EPS or unsupported management goals. ## Which stock lists is Kronox Lab Sciences on? Kronox Lab Sciences is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 721.1241275636207](https://www.sectoralpha.in/momentum-stocks-india)

## Is Kronox Lab Sciences profitable? Kronox Lab Sciences Ltd earned ₹7.3 Cr of net profit in the Jun 2026 quarter, +16.2% on the same quarter a year earlier. That is the 8th quarter in a row of profit growth. Full-year FY26 profit was ₹28.0 Cr. Over 6 years profit has grown 20.8% a year on average. That is 25.7% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr. For the full year, FY26 profit was ₹28.0 Cr (+12.0% on the year before). Why profit moved: revenue changed +16.9% on a year earlier and the margin moved −1.1 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +11.7% and revenue +6.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Kronox Lab Sciences make, and is it growing? Kronox Lab Sciences Ltd reported ₹28.4 Cr of revenue in the Jun 2026 quarter, +16.9% on the same quarter a year earlier. Over 6 years it has grown 12.4% a year on average. The last full year, FY26, came in at ₹101 Cr. The last four reported quarters add to ₹105 Cr. FY26 revenue was ₹101 Cr, +1.0% on the year before. Recent pace: the last four quarters grew +6.2% on average, against 12.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +6.1%, against +8.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.6%, against +16.3% a year (rolling over). ## How much of every ₹100 of sales does Kronox Lab Sciences keep? Kronox Lab Sciences Ltd's operating margin was 31.7% in the Jun 2026 quarter, 1.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 7 years it has been between 23.0% and 34.0%. The latest quarter is within that range. Why this happened. June revenue increased 16.9% and operating profit increased 12.8%. The business retained additional operating profit, but margin declined because operating profit grew more slowly than sales. Volume, price and mix contributions are unknown; competitor response and customer benefit retention cannot be established. The benefit already delivered is visible in the result, while persistence remains a forecast. Why the margin moved: operating margin changed −1.1 percentage points on the year while gross margin changed −0.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Kronox Lab Sciences' profit turning into cash? Over the last 3 years, 97% of Kronox Lab Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹24.0 Cr of operating cash against ₹28.0 Cr of profit. After ₹3.0 Cr of spending on assets, ₹21.0 Cr was left over as free cash. Why this happened. The Self-Funded Growth Engine applies to the historical cash record: aggregate operating cash flow broadly tracks profit and estimated free cash flow remains positive. This establishes past funding capacity, not the economics of a future plant. Construction expenditure and working-capital needs could reduce the cash available to shareholders. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 97% of profit came in as cash: the cash cycle got 11 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 4.5× depreciation over three years. The next section checks what that spending is building. ## Where does Kronox Lab Sciences' cash go? Kronox Lab Sciences Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 90 days in FY26, up from 79 days in FY21. It spent ₹18.0 Cr on assets over the last 3 years. Customers take 76 days to pay, and stock sits for 66 days on average. Why this happened. The annual report acknowledges that work had not started and goals production in two years and full operation in three years. The Capex Inflection Point therefore does not support a near-term contribution. Construction, qualification, utilization and incremental cash returns remain separate hurdles. No Dahej earnings contribution is included as delivered performance, and the relative schedule does not establish a verified commissioning date. At FY26 sales of ₹101 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹25.0 Cr is tied up in the business at any time. FY26: customers took 76 days to pay and stock sat for 66 days, about 2.2 months of sales sitting as stock, for a full cycle of 90 days, longer than FY21's 79. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 66 days. Customers pay about 76 days after that. Suppliers are paid at 52 days. Together that makes the 90-day cycle. Spending on assets: ₹18.0 Cr over the last 3 years, against ₹4.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Kronox Lab Sciences' P/E ratio, and how does it compare with its own history? Kronox Lab Sciences Ltd's P/E is 25.7×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 23.3×, over 2.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Kronox Lab Sciences share price assume? Worked out from its price on 11 October 2026, Kronox Lab Sciences Ltd's share price assumed profit growth of about 14.8% a year. Over the past 6 years its profit actually grew 20.8% a year. Today its P/E is 25.7×, higher than 65% of its own last 2.4 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Kronox Lab Sciences business getting better or worse? Kronox Lab Sciences Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 37.2%; each line tells part of the story. This is based on 11 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## What is the Kronox Lab Sciences story, and has it been checked? Kronox Lab Sciences Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: TROUGH. Still open: A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. Our read, 10 October 2026. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration. From the numbers. The supplied operating engine places the business near a trough, with earnings recovering; the separate price curve is in stage 2. The operating classification is tentative because June margin declined and the…

From the price. Price stage 2, week 18, above its 200-day line, relative strength rising. From the research. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration. Where they disagree. The supplied operating engine places the business near a trough, with earnings recovering; the separate price curve is in stage 2. What is proven. Cash-backed earnings provide a foundation, but treasury income and delayed expansion limit the case for an operating acceleration. What is not proven yet. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. What would change our mind. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. The test written in advance. A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. Measured by: the thesis as written as stated by the next result. What the surface reading misses. The surface reading is: Higher sales and profit suggest an acceleration. The research reads it further: Operating profit grew more slowly than revenue, so the result demonstrates additional sales without operating-leverage confirmation. What the surface reading misses. The surface reading is: Profit growth appears to signal rapid business expansion. The research reads it further: Sales were unchanged; improved operating margin, rather than revenue expansion, explains the observable operating improvement. Sources: our stock research file (10 October 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes. ## How much does Kronox Lab Sciences earn on its capital? Kronox Lab Sciences Ltd earned a ROCE of 36% in FY26. Its return on capital used (ROIC) is 23.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 27.7% net margin and 0.79× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 27.7% net margin × 0.79× asset turnover × 1.10× leverage (assets divided by equity) ≈ 24.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 35.7% − 12.0% = +23.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 35.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 39.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Kronox Lab Sciences have too much debt? Kronox Lab Sciences Ltd had ₹2.0 Cr of borrowings against ₹116 Cr of equity in FY26, so its debt is 0.02× its equity. Over 5 years borrowings went from ₹4.0 Cr to ₹2.0 Cr. Over the last 3 of those years it spent ₹18.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Kronox Lab Sciences shareholding pattern? Promoters cut their stake in Kronox Lab Sciences Ltd by 9.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 64.3% of the company. Foreign institutions moved −0.5 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −9.9 points over 8 quarters, to 64.3%; Foreign institutions: −0.5 points over 8 quarters, to 0.1%; Domestic institutions: +0.0 points over 8 quarters, to 2.5%. Why the owners changed: promoters drove it (−9.9 points), together with foreign institutions (−0.5 points). They reduced their stake. ## How far is Kronox Lab Sciences from balance-sheet trouble? For Kronox Lab Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Kronox Lab Sciences rank in its industry? 51.8 out of 100, rank 15 of 30 in Speciality Chemicals, with 74% of the evidence available. Kronox Lab Sciences Ltd scores 51.8 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 10.4 + 21.4 + 8.2 + 11.8 = 51.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Kronox Lab Sciences compared with? Kronox Lab Sciences ranks 15 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 51.8 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · turning · Sector-leading setup · 96% evidence 80.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.8/35 · Revenue 45.9% · Profit 100% · Operating margin change 14 points · 88% evidence Capital efficiency 15.9/25 · ROCE 19.2% · Operating margin 22% · 100% evidence Valuation 19.7/20 · P/E 5.7× · PEG 0.18 · 100% evidence Relative strength 13.9/20 · Lead over its industry 16.3% · Lead over NIFTY 500 31.3% · 1 year 68.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 30.8 + 15.9 + 19.7 + 13.9 = 80.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Most evidence points up · 78% evidence 67.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 8.9% · Operating margin 21% · 100% evidence Valuation 12.7/20 · P/E 45× · PEG 1.02 · 65% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 41.1% · 1 year 103.4% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30 + 12.3 + 12.7 + 12.2 = 67.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 68% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change 8 points · 83% evidence Capital efficiency 21.3/25 · ROCE 36.2% · Operating margin 48% · 95% evidence Valuation 6.6/20 · P/E 25.8× · PEG n/a · 50% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 74.5% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 21.3 + 6.6 + 12.5 = 64.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 12.9% · Profit 100% · Operating margin change 5 points · 88% evidence Capital efficiency 18.8/25 · ROCE 19.9% · Operating margin 16% · 100% evidence Valuation 10.8/20 · P/E 24.3× · PEG 2.21 · 100% evidence Relative strength 10.8/20 · Lead over its industry n/a · Lead over NIFTY 500 4.3% · 1 year -4% · 25% evidence · 0 of 5 weeks ahead Exact sum: 23.6 + 18.8 + 10.8 + 10.8 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Evidence leans up · 81% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 8.6% · Profit 28.6% · Operating margin change 6 points · 88% evidence Capital efficiency 16.4/25 · ROCE 18.7% · Operating margin 16% · 100% evidence Valuation 10.0/20 · P/E 17.1× · PEG 4.96 · 100% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 4.4% · 1 year n/a · 25% evidence · 7 of 12 weeks ahead Exact sum: 23.6 + 16.4 + 10 + 10.9 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) TATVA · losing its lead · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.7/25 · ROCE 7.2% · Operating margin 19% · 100% evidence Valuation 11.3/20 · P/E 60.2× · PEG 1.21 · 65% evidence Relative strength 11.4/20 · Lead over its industry 7.8% · Lead over NIFTY 500 23.3% · 1 year 15.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.7 + 8.7 + 11.3 + 11.4 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · leader · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 30.2% · Profit 28.4% · Operating margin change 1 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.9% · Operating margin 32% · 100% evidence Valuation 9.7/20 · P/E 85.1× · PEG n/a · 50% evidence Relative strength 14.8/20 · Lead over its industry 22.3% · Lead over NIFTY 500 38.6% · 1 year 114.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.4 + 12.8 + 9.7 + 14.8 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.5/25 · ROCE 22.3% · Operating margin 26% · 76% evidence Valuation 10.1/20 · P/E 33.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Lead over its industry -9.7% · Lead over NIFTY 500 4.2% · 1 year 10.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 23.7 + 18.5 + 10.1 + 7.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 96% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.3/35 · Revenue 91.5% · Profit 41% · Operating margin change -2 points · 88% evidence Capital efficiency 13.5/25 · ROCE 18.3% · Operating margin 16% · 100% evidence Valuation 5.7/20 · P/E 46.1× · PEG 1.92 · 100% evidence Relative strength 19.5/20 · Lead over its industry 34.1% · Lead over NIFTY 500 48.9% · 1 year 62.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.3 + 13.5 + 5.7 + 19.5 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans up · 93% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 72.1% · Profit 34.5% · Operating margin change -6.9 points · 100% evidence Capital efficiency 8.7/25 · ROCE 14.8% · Operating margin 4.2% · 100% evidence Valuation 16.1/20 · P/E 16.9× · PEG 0.44 · 65% evidence Relative strength 7.8/20 · Lead over its industry -12.3% · Lead over NIFTY 500 0.9% · 1 year -15.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22.9 + 8.7 + 16.1 + 7.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative
12. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · leader · Evidence leans up · 81% evidence 53.9 out of 100 Growth Capital Valuation Relative
13. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative
14. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative
15. Kronox Lab Sciences Ltd this page KRONOX · breaking out · Evidence leans up · 74% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.4/35 · Revenue 6.1% · Profit 11.6% · Operating margin change -1.1 points · 88% evidence Capital efficiency 21.4/25 · ROCE 36% · Operating margin 31.7% · 100% evidence Valuation 8.2/20 · P/E 24.2× · PEG 2.48 · 65% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.8% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 10.4 + 21.4 + 8.2 + 11.8 = 51.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Neogen Chemicals Ltd](https://www.sectoralpha.in/stocks/neogen-chemicals-ltd) NEOGEN · leader · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative
17. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 85% evidence 51.1 out of 100 Growth Capital Valuation Relative
18. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans down · 96% evidence 47.9 out of 100 Growth Capital Valuation Relative
19. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) GRAUWEIL · breaking out · Evidence leans down · 96% evidence 46.3 out of 100 Growth Capital Valuation Relative
20. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans down · 85% evidence 45.8 out of 100 Growth Capital Valuation Relative
21. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 53% evidence 44.0 out of 100 Growth Capital Valuation Relative
22. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ANURAS · turning · Evidence leans down · 78% evidence 43.7 out of 100 Growth Capital Valuation Relative
23. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 81% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 42.4 out of 100 Growth Capital Valuation Relative
25. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 41.5 out of 100 Growth Capital Valuation Relative
26. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
27. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) TRANSPEK · losing its lead · Evidence leans down · 63% evidence 38.6 out of 100 Growth Capital Valuation Relative
28. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 100% evidence 38.4 out of 100 Growth Capital Valuation Relative
29. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · breaking out · Evidence leans down · 85% evidence 38.1 out of 100 Growth Capital Valuation Relative
30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 68% evidence 27.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Kronox Lab Sciences in size? Kronox Lab Sciences is the 24th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Vikram Thermo (India), Sunshield Chemicals and Amines & Plasticizers. Just below it: Transpek Industry, Chemcon Speciality Chemicals and Amal. ### Speciality Chemicals companies close in size

1. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) ₹1,129 crore
2. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) ₹882 crore
3. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) ₹782 crore
4. Kronox Lab Sciences Ltd ₹691 crore
5. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) ₹682 crore
6. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) ₹666 crore
7. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) ₹658 crore

[All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies)

### Companies close in size in other industries

1. [Automotive Stampings & Assemblies Ltd](https://www.sectoralpha.in/stocks/automotive-stampings-assemblies-ltd) ₹695 crore · Auto Ancillaries - Spare Parts Accessories
2. [SRIT India Ltd](https://www.sectoralpha.in/stocks/srit-india-ltd) ₹692 crore
3. Kronox Lab Sciences Ltd ₹691 crore
4. [RBZ Jewellers Ltd](https://www.sectoralpha.in/stocks/rbz-jewellers-ltd) ₹690 crore · Diamond, Gems & Jewellery
5. [Vascon Engineers Ltd](https://www.sectoralpha.in/stocks/vascon-engineers-ltd) ₹690 crore · Construction & Contracting

## What else do people ask about Kronox Lab Sciences? ### What is Kronox Lab Sciences's share price today? Kronox Lab Sciences Ltd's share price is ₹197.70. The whole company is worth ₹734 Cr on the market. In the last 52 weeks it traded between ₹132 to ₹217; today it is 78% of the way up from the low, 21.0% above its 200-day average. The price has been rising for 18 weeks (as of 3 November 2026). ### What were Kronox Lab Sciences's latest quarterly results? Kronox Lab Sciences Ltd reported revenue of ₹28.4 Cr and net profit of ₹7.3 Cr for the Jun 2026 quarter. Revenue rose 16.9% and profit rose 16.2% compared with a year earlier. Earnings per share were ₹1.97. The operating margin was 31.7%, 1.1 percentage points lower than a year earlier (as of 3 November 2026). ### What is Kronox Lab Sciences's market cap? Kronox Lab Sciences Ltd's market capitalisation is ₹734 Cr at a share price of ₹197.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Kronox Lab Sciences performing? Kronox Lab Sciences Ltd's share price has been rising for 18 weeks. In its latest quarter, revenue rose 16.9% and profit rose 16.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 15 weeks running (as of 3 November 2026). ### Will Kronox Lab Sciences's share price go up? This page does not forecast Kronox Lab Sciences Ltd's share price. What it shows instead: the share price is ₹197.70, and it has been rising for 18 weeks. Its P/E of 25.7× is higher than 65% of its own last 2 years (as of 3 November 2026). ### Who owns Kronox Lab Sciences? Promoters own 64.3% of Kronox Lab Sciences Ltd, foreign institutions 0.1%, domestic institutions 2.5% and the public 33.1% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 9.9 percentage points over 8 quarters (as of 3 November 2026). ### Where is Kronox Lab Sciences in its business cycle? Kronox Lab Sciences Ltd's FY26 operating margin was 34.0%, against a 7-year range of 23.0% to 34.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 31.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Kronox Lab Sciences story? The main question: promoters moved −9.9 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Kronox Lab Sciences a stock worth studying right now? What the numbers show: Kronox Lab Sciences Ltd is reporting record margins. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Kronox Lab Sciences share price forecast for 2026? What is changing at Kronox Lab Sciences, from the latest results and calls: sales recovery, cash-funded operating base and qualified product offering. What would change the story: A subsequent result showing falling sales and operating profit together, with continued inventory accumulation, would break the case that the latest sales improvement can sustain cash-backed earnings. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.